Specific Biologics is a Toronto-based, venture-backed biotechnology company developing precision gene-editing therapies for serious genetic diseases. Its proprietary two-site Dualase platform is designed to precisely remove disease-causing DNA repeat expansions while preserving normal DNA sequences, delivered within a single AAV or via lipid nanoparticle-delivered mRNA. Its lead program targets C9ORF72-associated ALS, the most common known inherited genetic cause of the disease.
1
Round
1
Industry
4
Tags
Nov 2, 2026
Latest raise
Funding activity · 1 round
Nov 2, 2026
$35M
Series A
Led by Hatteras Venture Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
